Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (25)
Michele Carbone, Daniel R. Gomez, Anne S. Tsao, Haining Yang & Harvey I. Pass. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
17
.
Vanessa Martínez-Rivera, María Negrete-García, Federico Ávila-Moreno & Blanca Ortiz-Quintero. (2018) Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma. International Journal of Molecular Sciences 19:2, pages 595.
Crossref
Crossref
Daniel R. Gomez, Anne S. Tsao, Haining Yang & Harvey I. Pass. 2016. Holland-Frei Cancer Medicine. Holland-Frei Cancer Medicine
1
16
.
Eva María García Atienza, Carmen Llanos Val Jiménez, Soledad Navarro Ruiz & Jesús López-Torres Hidalgo. (2017) Mesotelioma pleural maligno. Medicina Paliativa 24:1, pages 47-50.
Crossref
Crossref
C.D. Hoang & R.A. Kratzke. 2017. Translating MicroRNAs to the Clinic. Translating MicroRNAs to the Clinic
203
221
.
Marjorie G. Zauderer. 2017. Asbestos and Mesothelioma. Asbestos and Mesothelioma
313
345
.
KAZUO YAMAMOTO, MASAHIRO SEIKE, SUSUMU TAKEUCHI, CHIE SOENO, AKIHIKO MIYANAGA, RINTARO NORO, YUJI MINEGISHI, KAORU KUBOTA & AKIHIKO GEMMA. (2014) miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. Oncology Reports 32:6, pages 2365-2372.
Crossref
Crossref
Eric Gustavo Ramírez-Salazar, Luis Carlos Salinas-Silva, Maria Eugenia Vázquez-Manríquez, Luis Vicente Gayosso-Gómez, Maria Cristina Negrete-Garcia, Sandra Lizbeth Ramírez-Rodriguez, Raúl Chávez, Edgar Zenteno, Patricio Santillán, Javier Kelly-García & Blanca Ortiz-Quintero. (2014) Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets. Experimental and Molecular Pathology 97:3, pages 375-385.
Crossref
Crossref
M Cioce, F Ganci, V Canu, A Sacconi, F Mori, C Canino, E Korita, B Casini, G Alessandrini, A Cambria, M A Carosi, R Blandino, V Panebianco, F Facciolo, P Visca, S Volinia, P Muti, S Strano, C M Croce, H I Pass & G Blandino. (2013) Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 33:46, pages 5319-5331.
Crossref
Crossref
A. Truini, S. Coco, A. Alama, C. Genova, C. Sini, M. G. Dal Bello, G. Barletta, E. Rijavec, G. Burrafato, F. Boccardo & F. Grossi. (2014) Role of microRNAs in malignant mesothelioma. Cellular and Molecular Life Sciences 71:15, pages 2865-2878.
Crossref
Crossref
Pamela E. Blackshear, Arun R. Pandiri, Thai-Vu T. Ton, Natasha P. Clayton, Keith R. Shockley, Shyamal D. Peddada, Kevin E. Gerrish, Robert C. Sills & Mark J. Hoenerhoff. (2013) Spontaneous Mesotheliomas in F344/N Rats Are Characterized by Dysregulation of Cellular Growth and Immune Function Pathways. Toxicologic Pathology 42:5, pages 863-876.
Crossref
Crossref
Yue Xu, Ming Zheng, Robert E. Merritt, Joseph B. Shrager, Heather A. Wakelee, Robert A. Kratzke & Chuong D. Hoang. (2013) miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. Chest 144:5, pages 1632-1643.
Crossref
Crossref
A G Manente, D Valenti, G Pinton, P V Jithesh, A Daga, L Rossi, S G Gray, K J O'Byrne, D A Fennell, R A Vacca, S Nilsson, L Mutti & L Moro. (2013) Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis 2:9, pages e72-e72.
Crossref
Crossref
KOZO KURIBAYASHI, SHIGERU MIYATA, KAZUYA FUKUOKA, AKI MURAKAMI, SYUSAI YAMADA, KUNIHIRO TAMURA, NORIKO HIRAYAMA, TAKAYUKI TERADA, CHIHARU TABATA, YOSHIHIRO FUJIMORI & TAKASHI NAKANO. (2013) Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma. Molecular and Clinical Oncology 1:4, pages 639-642.
Crossref
Crossref
Emin Tamer Elkiran, Mehmet Ali Kaplan, Alper Sevinc, Sercan Aksoy, Umut Demirci, Mesut Seker, Hakan Harputluoglu, Nuriye Yildirim Ozdemir, Feridun Isik, Arife Ulas, Mevlude Inanc, Ulku Yalcintas Arslan, Gamze Gokoz Dogu, Abdurrahman Isikdogan & Suleyman Buyukberber. (2012) Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Medical Oncology 29:5, pages 3147-3154.
Crossref
Crossref
Silvano Dragonieri, Marc P. van der Schee, Tommaso Massaro, Nunzia Schiavulli, Paul Brinkman, Armando Pinca, Pierluigi Carratú, Antonio Spanevello, Onofrio Resta, Marina Musti & Peter J. Sterk. (2012) An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls. Lung Cancer 75:3, pages 326-331.
Crossref
Crossref
C M Goparaju, J D Blasberg, S Volinia, J Palatini, S Ivanov, J S Donington, C Croce, M Carbone, H Yang & H I Pass. (2011) Onconase mediated NFKβ downregulation in malignant pleural mesothelioma. Oncogene 30:24, pages 2767-2777.
Crossref
Crossref
Mir Alireza Hoda, Amir Mohamed, Bahil Ghanim, Martin Filipits, Balazs Hegedus, Masaya Tamura, Judit Berta, Bernd Kubista, Balazs Dome, Michael Grusch, Ulrike Setinek, Michael Micksche, Walter Klepetko & Walter Berger. (2011) Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy. Journal of Thoracic Oncology 6:5, pages 852-863.
Crossref
Crossref
E. Barcina García, M.C. Álvarez Sanz, P. Quintana Valcarcel & B. Sánchez Cordón. (2011) Solución del caso 26. Mesotelioma pleural maligno. Radiología 53:1, pages 83-85.
Crossref
Crossref
G. de Gennaro, S. Dragonieri, F. Longobardi, M. Musti, G. Stallone, L. Trizio & M. Tutino. (2010) Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure. Analytical and Bioanalytical Chemistry 398:7-8, pages 3043-3050.
Crossref
Crossref
Gerd R. Silberhumer, Peter Brader, Joyce Wong, Inna S. Serganova, Mithat Gönen, Segundo Jaime Gonzalez, Ronald Blasberg, Dmitriy Zamarin & Yuman Fong. (2010) Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics 9:10, pages 2761-2769.
Crossref
Crossref
Pinar KARA, Işil UGUR, Cem MISIRLIOGLU, Bülent KÜCÜKPLAKCI, Aytul OZGEN, Yesim ELGIN, Taciser DEMIRKASIMOGLU & Ergun SANRI. (2010) Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma. Asia-Pacific Journal of Clinical Oncology 6:3, pages 187-190.
Crossref
Crossref
Harvey I. Pass, Chandra Goparaju, Sergey Ivanov, Jessica Donington, Michele Carbone, Moshe Hoshen, Dalia Cohen, Ayelet Chajut, Shai Rosenwald, Harel Dan, Sima Benjamin & Ranit Aharonov. (2010) hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma. Cancer Research 70:5, pages 1916-1924.
Crossref
Crossref
Amanda K Beck, Harvey I Pass, Michele CarboneHaining Yang. (2008) Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncology 4:3, pages 341-349.
Crossref
Crossref
Haining Yang, Joseph R. Testa & Michele Carbone. (2008) Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis. Current Treatment Options in Oncology 9:2-3, pages 147-157.
Crossref
Crossref